Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Autoimmune Disorders01:29

Autoimmune Disorders

2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.4K
Overview
64.4K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.5K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

13.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
13.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Resident Perception and Program Response of Annual Institutional Internal Survey in COVID Era: A 6 Year Analysis.

The American surgeon·2025
Same author

Predictors of Intensive Care Unit Admissions in Patients Presenting with Coronavirus Disease 2019.

Avicenna journal of medicine·2024
Same author

Peer review journal publication rates of award-winning presentations from a multi-disciplinary multi-institutional medical education consortium annual research forum: 40-year experience.

American journal of surgery·2023
Same author

Incentives as a Driving Force for Scholarly Activity in General Surgery Training: Survey of Program Directors and our Institution's Experience.

The American surgeon·2023
Same author

Publication rates of annual Research Day abstracts in peer-reviewed journals by residents and fellows at a community-based institution - A 10-year review of data and analysis.

Heliyon·2023
Same author

Corrigendum to "Determinants of all-cause in-hospital mortality among patients who presented with COVID-19 to a community teaching hospital in Michigan" [Heliyon 7 (12) (December 2021), Article e08566].

Heliyon·2022

Related Experiment Video

Updated: Apr 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.

Yi-Chi M Kong1, Jeffrey C Flynn2

  • 1Department of Immunology and Microbiology, Wayne State University School of Medicine , Detroit, MI , USA.

Frontiers in Immunology
|June 7, 2014
PubMed
Summary

Immune-checkpoint inhibitors like anti-CTLA-4 show promise in cancer immunotherapy, despite causing autoimmune side effects. Combinations with other therapies aim to improve overall survival and manage these immune-related adverse events.

Keywords:
anti-CTLA-4anti-PD-1autoimmune diseaseimmune-checkpoint inhibitortumor immunity

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

Related Experiment Videos

Last Updated: Apr 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

Area of Science:

  • Immunology
  • Oncology
  • Autoimmunity

Background:

  • Clinical trials are exploring immunotherapies targeting specific pathways to enhance cancer treatment and manage autoimmune diseases.
  • Immune-checkpoint inhibitors, particularly anti-CTLA-4 (e.g., ipilimumab), are investigated for their efficacy and associated immune-related adverse events (irAEs).
  • Despite irAEs in ~60% of patients, ipilimumab demonstrates an average 3-5 year overall survival of 22-25%.

Purpose of the Study:

  • To review immune-checkpoint inhibitors, focusing on anti-CTLA-4 and emerging therapies targeting PD-1/PD-L1.
  • To discuss the therapeutic potential and autoimmune sequelae of these immunotherapies.
  • To explore the balance between tumor immunity and autoimmunity using murine models.

Main Methods:

  • Review of clinical trial data for anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
  • Analysis of therapeutic combinations and their potential impact on autoimmune disorders.
  • Application of regulatory T cell perturbation in murine models to study thyroid autoimmunity and tumor immunity.

Main Results:

  • Anti-CTLA-4 therapy, while effective, is associated with significant immune-related adverse events.
  • Combination therapies involving anti-CTLA-4 and agents targeting PD-1/PD-L1 are under investigation to improve overall survival.
  • Murine models are used to simulate clinical scenarios and investigate the interplay between tumor immunity and induced autoimmunity.

Conclusions:

  • Immune-checkpoint inhibitors represent a significant advancement in cancer immunotherapy, but managing irAEs remains crucial.
  • Combination strategies hold promise for enhancing treatment efficacy and survival rates.
  • Further research, including preclinical models, is essential to understand and balance anti-tumor responses with the risk of autoimmune complications.